These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21088436)

  • 1. Does the metastatic lymph node ratio influence the disease-free survival of patients with breast cancer: single-center experiences.
    Oven Ustaalioglu BB; Bilici A; Kefeli U; Seker M; Yildirim E; Salepci T; Oncel M; Kement M; Gumus M
    Oncology; 2010; 79(1-2):105-11. PubMed ID: 21088436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
    Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ratio between positive lymph nodes and total excised axillary lymph nodes as an independent prognostic factor for overall survival in patients with nonmetastatic lymph node-positive breast cancer.
    Hatoum HA; Jamali FR; El-Saghir NS; Musallam KM; Seoud M; Dimassi H; Abbas J; Khalife M; Boulos FI; Tawil AN; Geara FB; Salem Z; Shamseddine AA; Al-Feghali K; Shamseddine AI
    Ann Surg Oncol; 2009 Dec; 16(12):3388-95. PubMed ID: 19655200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sentinel lymph node biopsy alone has no adverse impact on the survival of patients with breast cancer.
    Takei H; Suemasu K; Kurosumi M; Horii Y; Ninomiya J; Yoshida M; Hagiwara Y; Inoue K; Tabei T
    Breast J; 2006; 12(5 Suppl 2):S157-64. PubMed ID: 16958996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
    Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer.
    Lale Atahan I; Yildiz F; Ozyigit G; Sari S; Gurkaynak M; Selek U; Hayran M
    Acta Oncol; 2008; 47(2):232-8. PubMed ID: 17924207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
    Pierga JY; Mouret E; Diéras V; Laurence V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Vincent-Salomon A; Scholl S; Extra JM; Asselain B; Pouillart P
    Br J Cancer; 2000 Dec; 83(11):1480-7. PubMed ID: 11076657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
    Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
    Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors affecting survival and disease-free survival in lymph node-negative breast carcinomas.
    Kuru B; Camlibel M; Gulcelik MA; Alagol H
    J Surg Oncol; 2003 Jul; 83(3):167-72. PubMed ID: 12827686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical impact of extracapsular extension of axillary lymph node metastases in breast cancer].
    Zhang B; Cao WF; Zhao HM; Song YQ; Ning LS; Niu Y; Hao XS; Cao XC
    Zhonghua Zhong Liu Za Zhi; 2009 Oct; 31(10):790-4. PubMed ID: 20021837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A high number of tumor free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome.
    Camp RL; Rimm EB; Rimm DL
    Cancer; 2000 Jan; 88(1):108-13. PubMed ID: 10618612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
    Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymph node counts and ratio in axillary dissections following neoadjuvant chemotherapy for breast cancer: a better alternative to traditional pN staging.
    Chen S; Liu Y; Huang L; Chen CM; Wu J; Shao ZM
    Ann Surg Oncol; 2014 Jan; 21(1):42-50. PubMed ID: 24013900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of residual breast disease and axillary node involvement for patients who had primary induction chemotherapy for advanced breast cancer.
    Escobar PF; Patrick RJ; Rybicki LA; Hicks D; Weng DE; Crowe JP
    Ann Surg Oncol; 2006 Jun; 13(6):783-7. PubMed ID: 16604475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel data-driven prognostic model for staging of colorectal cancer.
    Manilich EA; Kiran RP; Radivoyevitch T; Lavery I; Fazio VW; Remzi FH
    J Am Coll Surg; 2011 Nov; 213(5):579-588, 588.e1-2. PubMed ID: 21925905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there any prognostically different subgroup among patients with stage IIIC (any TN3M0) breast carcinoma?
    Duraker N; Caynak ZC; Bati B
    Ann Surg Oncol; 2008 Feb; 15(2):430-7. PubMed ID: 17912589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The correlation of extranodal invasion with other prognostic parameters in lymph node positive breast cancer.
    Altinyollar H; Berberoğlu U; Gülben K; Irkin F
    J Surg Oncol; 2007 Jun; 95(7):567-71. PubMed ID: 17226805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sentinel node in the era of neoadjuvant therapy and locally advanced breast cancer.
    Trocha SD; Giuliano AE
    Surg Oncol; 2003 Dec; 12(4):271-6. PubMed ID: 14998567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.